Skip to main content
Corterve
10 Studies Recruiting

Clinical Trials Near Sacramento, CA

Find research studies actively recruiting participants near Sacramento. Studies are run at established research institutions including UC Davis Medical Center and Sutter Health.

Top Research Institutions in Sacramento

1

UC Davis Medical Center

2

Sutter Health

Recruiting Studies Near Sacramento

#1

Connect-One: Early Feasibility Study of Connexusยฎ Brain-Computer Interface (BCI)

RECRUITINGNAParadromics

The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communication as a result of severe loss of voluntary motor control; and (2) to provide control of computer devices for individuals with severe loss of voluntary motor control of the upper extremity.

๐Ÿ“ Sacramento, California๐Ÿ“ Boston, Massachusetts๐Ÿ“ Ann Arbor, Michigan
#2

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

RECRUITINGPHASE3Pierre Fabre Medicament

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

๐Ÿ“ Loma Linda, California๐Ÿ“ Los Angeles, California๐Ÿ“ Washington D.C., District of Columbia
#3

A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury

RECRUITINGNot SpecifiedHoffmann-La Roche

The study is intended to cover two purposes: first, to develop a blood-based biomarker test for aiding the diagnosis of traumatic brain injury (TBI) in adult participants and for prognosis of outcome of TBI (CLIN12.1); and second, for monitoring the development of secondary events in adult participants diagnosed with TBI (CLIN12.2).

๐Ÿ“ Sacramento, California๐Ÿ“ San Francisco, California๐Ÿ“ Charlotte, North Carolina
#4

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

RECRUITINGPHASE3Eli Lilly and Company

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

๐Ÿ“ Birmingham, Alabama๐Ÿ“ Phoenix, Arizona๐Ÿ“ Scottsdale, Arizona
#5

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

RECRUITINGPHASE2Immunovant Sciences GmbH

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.

๐Ÿ“ Phoenix, Arizona๐Ÿ“ Huntington Beach, California๐Ÿ“ Los Angeles, California
#6

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

RECRUITINGPHASE3Intra-Cellular Therapies, Inc.

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

๐Ÿ“ Phoenix, Arizona๐Ÿ“ Little Rock, Arkansas๐Ÿ“ Anaheim, California
#7

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

RECRUITINGPHASE2Alliance for Clinical Trials in Oncology

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type of anti-androgen. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to tumor cells which damages and kills these cells. Assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing

๐Ÿ“ Birmingham, Alabama๐Ÿ“ Tucson, Arizona๐Ÿ“ Tucson, Arizona
#8

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

RECRUITINGPHASE3Basilea Pharmaceutica

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.

๐Ÿ“ Birmingham, Alabama๐Ÿ“ Duarte, California๐Ÿ“ Los Angeles, California
#9

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

RECRUITINGPHASE1University of California, Davis

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).

๐Ÿ“ Sacramento, California
#10

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

RECRUITINGPHASE3NRG Oncology

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

๐Ÿ“ Anchorage, Alaska๐Ÿ“ Anchorage, Alaska๐Ÿ“ Anchorage, Alaska

Clinical Trials in Sacramento: FAQ

How do I find clinical trials near Sacramento?

Corterve aggregates all actively recruiting clinical trials near Sacramento, CA from the ClinicalTrials.gov database. Simply browse the listings on this page or take our assessment to find trials that may be relevant.

Does it cost anything to take part in a study?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

What research institutions are located in Sacramento?

Sacramento is home to several leading research institutions, including UC Davis Medical Center, Sutter Health. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to see studies near you?

Take our assessment to see research studies recruiting near Sacramento that may be relevant. Study teams decide who joins.

See studies near you